Mechanical cues control mutant p53 stability through a mevalonate–RhoA axis

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Nature Cell Biology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1038/s41556-017-0009-8PMID 29255172PMCID PMC6179142
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Do Mutations Turn p53 into an Oncogene?

  2019cited by this paper
• Targeting mutant p53 in cancer: a long road to precision therapy

  2017cited by this paper
• Glucocorticoid receptor signalling activates YAP in breast cancer

  2017cited by this paper
• YAP/TAZ at the Roots of Cancer.

  2016cited by this paper
• DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway

  2016cited by this paper
• The interplay between cell signalling and the mevalonate pathway in cancer

  2016cited by this paper
• Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth

  2015cited by this paper
• TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance

  2014cited by this paper
• Metabolic control of YAP and TAZ by the mevalonate pathway

  2014cited by this paper
• Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status

  2014cited by this paper
• Geranylgeranylation signals to the Hippo pathway for breast cancer cell proliferation and migration

  2014cited by this paper
• Tumor-Associated Mutant p53 Drives the Warburg Effect

  2013cited by this paper
• A mechanical checkpoint controls multicellular growth through YAP/TAZ regulation by actin-processing factors.

  2013cited by this paper
• Correction: Corrigendum: The tRNA methyltransferase NSun2 stabilizes p16INK4 mRNA by methylating the 3′-untranslated region of p16

  2013cited by this paper
• Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility

  2013cited by this paper
• Prolyl-isomerase Pin1 controls normal and cancer stem cells of the breast

  2013cited by this paper
• Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway.

  2012cited by this paper
• Mutant p53: one name, many proteins.

  2012cited by this paper
• Statins Promote the Regression of Atherosclerosis via Activation of the CCR7-Dependent Emigration Pathway in Macrophages

  2011cited by this paper
• SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis

  2011cited by this paper
• A Pin1/mutant p53 axis promotes aggressiveness in breast cancer.

  2011cited by this paper
• Differential effects of sulforaphane on histone deacetylases, cell cycle arrest and apoptosis in normal prostate cells versus hyperplastic and cancerous prostate cells.

  2011cited by this paper
• Mechanisms of mechanical signaling in development and disease

  2011cited by this paper
• A stress response pathway regulates DNA damage through β2-adrenoreceptors and β-arrestin-1

  2011cited by this paper
• Li-fraumeni syndrome.

  2011cited by this paper
• Cardiac glycosides inhibit p53 synthesis by a mechanism relieved by Src or MAPK inhibition.

  2009cited by this paper
• A tense situation: forcing tumour progression

  2009cited by this paper
• Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2.

  2008cited by this paper
• The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss.

  2008cited by this paper
• HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination

  2007cited by this paper
• Ubiquitination and Degradation of Mutant p53

  2007cited by this paper
• Cellular mechanotransduction: putting all the pieces together again

  2006cited by this paper
• HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor.

  2005cited by this paper
• A novel Rho-mDia2-HDAC6 pathway controls podosome patterning through microtubule acetylation in osteoclasts

  2005cited by this paper
• The Chaperone-associated Ubiquitin Ligase CHIP Is Able to Target p53 for Proteasomal Degradation*

  2005cited by this paper
• An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival.

  2005cited by this paper
• The Presence of a Fibrotic Focus in Invasive Breast Carcinoma Correlates with the Expression of Carbonic Anhydrase IX and is a Marker of Hypoxia and Poor Prognosis

  2003cited by this paper
• Feeling the forces: atomic force microscopy in cell biology.

  2003cited by this paper
• Exploration, normalization, and summaries of high density oligonucleotide array probe level data.

  2003cited by this paper
• In silico prediction of protein-protein interactions in human macrophages

  2001cited by this paper
• Heterogeneous distribution of P53 immunoreactivity in human lung adenocarcinoma correlates with MDM2 protein expression, rather than with P53 gene mutation

  2001cited by this paper
• Role of extracellular matrix assembly in interstitial transport in solid tumors.

  2000cited by this paper
• Regulation of p53 stability

  1999cited by this paper
• The stabilization mechanism of mutant-type p53 by impaired ubiquitination: the loss of wild-type p53 function and the hsp90 association

  1999cited by this paper
• The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor.

  1997cited by this paper
• Protein prenylation: molecular mechanisms and functional consequences.

  1996cited by this paper
• Post-translational isoprenylation of cellular proteins is altered in response to mevalonate availability.

  1989cited by this paper
• The relation between load and penetration in the axisymmetric boussinesq problem for a punch of arbitrary profile

  1965cited by this paper

• The p53 R181C mutation accumulates through impaired deacetylation by Sirt1 and facilitates tumor development

  2026cites this paper
• Innovative Drug and Prodrug Candidates in Cancer Treatment Targeting TP53 Mutations: Challenge and Hope

  2026cites this paper
• Metabolic remodeling and immune evasion in glioblastoma: a focus on serine and lipid networks.

  2026cites this paper
• Targeting RhoA nuclear mechanoactivity rejuvenates aged hematopoietic stem cells

  2025cites this paper
• Mutant p53 Regulates Pyruvate Dehydrogenase Kinase 1 (PDK1) to Promote Proliferation and Migration in Breast Cancer

  2025cites this paper
• Mutant p53 regulates cancer cell invasion in complex three-dimensional environments through mevalonate pathway-dependent Rho/ROCK signaling.

  2025cites this paper
• Glucose metabolic dysregulation and oxidative stress in cholangiocarcinoma: molecular mechanisms, oncogenic drivers, and novel therapeutic targets

  2025cites this paper
• Research Advances in Protein Prenylation in Cardiovascular Diseases.

  2025cites this paper
• The relationship between statin use and breast cancer risk: NHANES 2003–2016 and Mendelian randomization study

  2025cites this paper
• Substrate stiffness regulates triple-negative breast cancer signaling through CXCR4 receptor dynamics

  2025influential citation
• Mechanical regulation of extracellular vesicle activity during tumour progression

  2025cites this paper
• Efficacy analysis of targeted P53 therapy in solid tumors

  2025cites this paper
• Mevalonate pathway in pancreatic ductal adenocarcinoma: Mechanisms driving metabolic and cellular plasticity

  2025cites this paper
• Proteomic landscape of decellularized breast carcinomas identifies C-type lectin domain family 3 member A as a driver of cancer aggressiveness

  2025cites this paper
• Discovery of Drugs Targeting Mutant p53 and Progress in Nano-Enabled Therapeutic Strategy for p53-Mutated Cancers

  2025cites this paper
• β-adrenergic signaling modulates breast cancer cell mechanical behaviors through a RhoA-ROCK-myosin II axis

  2025cites this paper
• Low-dose statins restore innate immune response in breast cancer cells via suppression of mutant p53

  2025cites this paper
• Primary cilia prevent activation of the cGAS-STING pathway during mouse decidualization

  2025cites this paper
• Lipogenic enzyme FASN promotes mutant p53 accumulation and gain-of-function through palmitoylation

  2025cites this paper
• Glutathione reductase underlies the stability of mutant p53 by antagonizing protein glutathionylation

  2025cites this paper
• Protein prenylation in mechanotransduction: implications for disease and therapy.

  2025cites this paper
• The (un)known crosstalk between metabolism and mechanotransduction: Implications for metabolic syndrome (MetS)-associated neurological complications.

  2025cites this paper
• Mutant p53: evolving perspectives

  2025cites this paper
• The interplay between extracellular matrix remodeling and cellular lipid metabolic reprogramming in cancer: a review

  2025cites this paper
• p53 Genetics and Biology in Lung Carcinomas: Insights, Implications and Clinical Applications

  2024cites this paper
• Deciphering the significance of p53 mutant proteins.

  2024cites this paper
• Are statins onco- suppressive agents for every type of tumor? A systematic review of literature

  2024cites this paper
• Cholesterol metabolism in tumor microenvironment: cancer hallmarks and therapeutic opportunities

  2024cites this paper
• Nanoparticles targeting mutant p53 overcome chemoresistance and tumor recurrence in non-small cell lung cancer

  2024cites this paper
• Amyloid aggregates induced by the p53-R280T mutation lead to loss of p53 function in nasopharyngeal carcinoma

  2024cites this paper
• Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials

  2023cites this paper
• p140Cap modulates the mevalonate pathway decreasing cell migration and enhancing drug sensitivity in breast cancer cells

  2023cites this paper
• Mechanistic Aspects of Biphenyl Urea-Based Analogues in Triple-Negative Breast Cancer Cell Lines.

  2023cites this paper
• p53R245W Mutation Fuels Cancer Initiation and Metastases in NASH-driven Liver Tumorigenesis

  2023cites this paper
• Mutant p53 murine oviductal epithelial cells induce progression of high-grade serous carcinoma and are most sensitive to simvastatin therapy in vitro and in vivo

  2023cites this paper
• Metastatic outgrowth via the two-way interplay of autophagy and metabolism.

  2023cites this paper
• Emerging roles and mechanisms of ERK pathway mechanosensing

  2023cites this paper
• Mutant p53 sustains serine-glycine synthesis and essential amino acids intake promoting breast cancer growth

  2023cites this paper
• Engineered a dual-targeting HA-TPP/A nanoparticle for combination therapy against KRAS-TP53 co-mutation in gastrointestinal cancers

  2023cites this paper
• Mechanotransduction in response to ECM stiffening impairs cGAS immune signaling in tumor cells.

  2023cites this paper
• Engineered hydrogel reveals contribution of matrix mechanics to esophageal adenocarcinoma and identifies matrix-activated therapeutic targets

  2023cites this paper
• Targeting Oncogenic Mutant p53 and BCL-2 for Small Cell Lung Cancer Treatment

  2023cites this paper
• The effects of statins in patients with advanced-stage cancers - a systematic review and meta-analysis

  2023cites this paper
• Dynamic links between mechanical forces and metabolism shape the tumor milieu.

  2023cites this paper
• The Development of p53-Targeted Therapies for Human Cancers

  2023cites this paper
• Precise pancreatic cancer therapy through targeted degradation of mutant p53 protein by cerium oxide nanoparticles

  2023cites this paper
• Ivermectin Augments the Anti-Cancer Activity of Pitavastatin in Ovarian Cancer Cells

  2023cites this paper
• Role of p53 in breast cancer progression: An insight into p53 targeted therapy

  2023cites this paper
• An extracellular matrix stiffness-induced breast cancer cell transcriptome resembles the transition from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC).

  2023cites this paper
• Cell Response to Mechanical Microenvironment Cues via Rho Signaling: From Mechanobiology to Mechanomedicine.

  2023cites this paper
• N6-methyladenosine modification in 18S rRNA promotes tumorigenesis and chemoresistance via HSF4b/HSP90B1/mutant p53 axis.

  2023cites this paper
• The ubiquitin ligase TRIM21 regulates mutant p53 accumulation and gain of function in cancer

  2023cites this paper
• Curriculum vitae of HDAC6 in solid tumors.

  2023cites this paper
• Inhibiting the Priming for Cancer in Li-Fraumeni Syndrome

  2022cites this paper
• RETRACTED ARTICLE: ROCK1 mechano-signaling dependency of human malignancies driven by TEAD/YAP activation

  2022cites this paper
• Malic enzyme 2 maintains protein stability of mutant p53 through 2-hydroxyglutarate

  2022cites this paper
• Fibrous stroma: Driver and passenger in cancer development

  2022cites this paper
• Malic enzyme 2 as a therapeutic target for cancer: comments on ‘Malic enzyme 2 maintains protein stability of mutant p53 through 2-hydroxyglutarate’

  2022cites this paper
• Statin Use and the Risk of Prostate Cancer Biochemical Recurrence Following Definitive Therapy: A Systematic Review and Meta-Analysis of Cohort Studies

  2022cites this paper
• The mevalonate pathway in breast cancer biology.

  2022cites this paper
• Cholesterol and Its Derivatives: Multifaceted Players in Breast Cancer Progression

  2022cites this paper
• Statins inhibit proliferation and induce apoptosis in triple-negative breast cancer cells

  2022influential citation
• Li–Fraumeni Syndrome: Mutation of TP53 Is a Biomarker of Hereditary Predisposition to Tumor: New Insights and Advances in the Treatment

  2022cites this paper
• Proteasomal and autophagy-mediated degradation of mutp53 proteins through mitochondria-targeting aggregation-induced-emission materials.

  2022cites this paper
• Mutant p53-driven lncRNA LINC00857 promotes pancreatic cancer metastasis through OTUB1- mediated FOXM1 deubiquitination

  2022cites this paper
• Migration and 3D Traction Force Measurements inside Compliant Microchannels.

  2022cites this paper
• Targeting Mutant p53 for Cancer Treatment: Moving Closer to Clinical Use?

  2022influential citation
• Mutant p53 driven-LINC00857, a protein scaffold between FOXM1 and deubiquitinase OTUB1, promotes the metastasis of pancreatic cancer.

  2022cites this paper
• Antidiabetic drug metformin suppresses tumorigenesis through inhibition of mevalonate pathway enzyme HMGCS1

  2022cites this paper
• Engineered hydrogel reveals contribution of matrix mechanics to esophageal adenocarcinoma 3D organoids and identify matrix-activated therapeutic targets

  2022cites this paper
• Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives

  2021cites this paper
• The degradation of Rap1GAP via E6AP-mediated ubiquitin-proteasome pathway is associated with HPV16/18-infection in cervical cancer cells

  2021cites this paper
• The role of p53/p21/p16 in DNA damage signaling and DNA repair

  2021cites this paper
• The p53 Protein Family in the Response of Tumor Cells to Ionizing Radiation: Problem Development

  2021cites this paper
• RhoA enhances osteosarcoma resistance to MPPa-PDT via the Hippo/YAP signaling pathway

  2021cites this paper
• Cell cycle dependence on the mevalonate pathway: role of cholesterol and non-sterol isoprenoids.

  2021cites this paper
• Suppression of HSF1 activity by wildtype p53 creates a driving force for p53 loss-of-heterozygosity

  2021cites this paper
• Cholesterol Metabolic Reprogramming in Cancer and Its Pharmacological Modulation as Therapeutic Strategy

  2021cites this paper
• RhoGTPase Signalling in Cancer Progression and Dissemination.

  2021cites this paper
• The Function of the Mutant p53-R175H in Cancer

  2021cites this paper
• Recent Advances of Wee1 Inhibitors and Statins in Gynecologic Cancers with p53 Mutations

  2021cites this paper
• Targeting Cholesterol Biosynthesis Promotes Anti-tumor Immunity by Inhibiting Long Noncoding RNA SNHG29 Mediated YAP Activation.

  2021cites this paper
• Mutant p53 in cell-cell interactions

  2021cites this paper
• The complexity of p53-mediated metabolic regulation in tumor suppression.

  2021cites this paper
• p53-R273H Sustains ROS, Pro-Inflammatory Cytokine Release and mTOR Activation While Reducing Autophagy, Mitophagy and UCP2 Expression, Effects Prevented by wtp53

  2021cites this paper
• Mutant p53 Gain-of-Function: Role in Cancer Development, Progression, and Therapeutic Approaches

  2021cites this paper
• Mutant p53 as a Regulator and Target of Autophagy

  2021cites this paper
• Cancer Stemness: p53 at the Wheel

  2021cites this paper
• Amplifying Tumor–Stroma Communication: An Emerging Oncogenic Function of Mutant p53

  2021cites this paper
• P53 in RhoA regulation

  2020cites this paper
• Buxus alkaloid compound destabilizes mutant p53 through inhibition of the HSF1 chaperone axis.

  2020cites this paper
• Suppression of MET Signaling Mediated by Pitavastatin and Capmatinib Inhibits Oral and Esophageal Cancer Cell Growth

  2020cites this paper
• Statin-induced GGPP depletion blocks macropinocytosis and starves cells with oncogenic defects

  2020influential citation
• Cholesterol and beyond - The role of the mevalonate pathway in cancer biology.

  2020cites this paper
• Targeting Triple Negative Breast Cancer with a Nucleus-Directed p53 Tetramerization Domain Peptide.

  2020cites this paper
• Fat and Furious: Lipid Metabolism in Antitumoral Therapy Response and Resistance.

  2020cites this paper
• Chaperones and Ubiquitin Ligases Balance Mutant p53 Protein Stability in Esophageal and Other Digestive Cancers

  2020cites this paper
• Enhancing Chemotherapy of p53‐Mutated Cancer through Ubiquitination‐Dependent Proteasomal Degradation of Mutant p53 Proteins by Engineered ZnFe‐4 Nanoparticles

  2020cites this paper
• Statins as anti-cancer agents in the era of precision medicine

  2020cites this paper
• Effect of simvastatin on cell proliferation and Ras activation in canine tumour cells.

  2020cites this paper